CYP19A1 and breast cancer: Among those patients who received adjuvant CMF (AUC = 0.6, p = 0.09), FAC (AUC = 0.53, p = 0.4), aromatase inhibitor (AUC = 0.61, p = 0.21), trastuzumab (AUC = 0.50, p = 0.48), taxane (AUC = 0.51, p = 0.14), and FEC (AUC = 0.56, p = 0.33), PTPRT might not predict the recurrence-free survival of the breast cancer patients.